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Abstract: It was long thought that most of brain creatine was of peripheral origin. However, recent 
works have demonstrated that creatine crosses blood-brain barrier only with poor efficiency, and that 
CNS must ensure parts of its creatine needs by its own creatine synthesis pathway, thank to the brain 
expression of AGAT and GAMT (creatine synthesis) and SLC6A8 (creatine transporter). This new 
understanding of creatine metabolism and transport in CNS allows a better comprehension of creatine 
deficiency syndromes, which are due to deficiencies in AGAT, GAMT and SLC6A8 and mainly affect 
the brain of patients who show severe neurodevelopmental delay and present neurological symptoms 
in early infancy. 
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1 Introduction 
The creatine (Cr) / phosphocreatine (PCr) / 
creatine kinase (CK) system plays essential roles 
to maintain the high energy levels necessary for 
brain development and functions, through 
regeneration and buffering of ATP levels [21,72]. 
The Cr/PCr/CK system also allows the shuttle of 
high-energy phosphates from mitochondria to 
their cytoplasmic sites of utilization [70]. Cr was 
also suggested recently as true neurotransmitter 
and one of the main central nervous system 
(CNS) osmolytes [3,9]. In mammals, pools of Cr 
are maintained through uptake from diet and 
endogenous synthesis. Cr biosynthesis involves 
L-arginine:glycine amidinotransferase (AGAT) 
yielding guanidinoacetate (GAA) from arginine 
and glycine,  and guanidinoacetate methyl-
transferase (GAMT), yielding Cr from GAA. Cr 
is distributed by blood to tissues, where cells take 
it up by a specific transporter, SLC6A8, also 
called CRT1, CT1, CreaT or CRT [72].  
It has long been thought that most, if not all, 
cerebral Cr was of peripheral origin [72]. 
However, AGAT and GAMT are expressed in 
CNS and brain cells synthesize their own Cr 
[11,20]. In contrast, while SLC6A8 is expressed 
by microcapillary endothelial cells (MCEC) at 
blood-brain barrier (BBB), allowing CNS to 
import Cr from periphery, it is absent from 
astrocytes and particularly from their feet lining 
MCEC [11,47,65]. This suggested that BBB has 
a limited permeability for peripheral Cr, and that 
CNS must supply an important part of its Cr 
needs by endogenous synthesis rather than on 
exclusive supply from the blood [6,11,18]. 
Recent data also suggest that in the brain, the Cr 
synthesis pathway may be dissociated as it is in 
periphery, the intermediate GAA being 
transported through SLC6A8 from AGAT- to 
GAMT-expressing cells for Cr synthesis to occur 
in CNS [15]. 
Cr deficiency syndromes are caused by 
mutations in AGAT, GAMT and SLC6A8 genes 
[38,53,62]. Their common phenotype is an 
almost complete lack of Cr in CNS, which 
appears as the main organ affected in these 
primary Cr deficiencies. Patients develop severe 
neurodevelopmental delay and present 
neurological symptoms in early infancy, like 
mental retardation, delays in speech acquisition 
or epilepsy [63]. Oral Cr supplementation 
strongly improves the neurological status of 
AGAT- and GAMT-deficient patients 
[5,55,58,61], while this treatment is inefficient on 
SLC6A8-deficient patients [4,7,51]. Secondary 
Cr deficiencies are also observed in other CNS 
pathological states, like stroke, hyperammonemic 
states or gyrate atrophy of the choroid and retina 
(GA) [6]. 
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This review is focused on the latest data on Cr 
synthesis and transport in CNS, in order to 
delineate a comprehensive frame on Cr 
metabolism and transport in the brain, both in 
normal and in the Cr-deficient conditions 
characteristic of Cr deficiency syndromes. 
 
2 Creatine in the brain 
 
2.1 Functions of creatine in CNS 
The Cr/PCr/CK system plays essential roles to 
maintain the high energy phosphates levels 
necessary for CNS (maintenance of membrane 
potential and ions gradients, Ca
++
 homeostasis, 
neurotransmission, intracellular signaling 
systems as well as axonal and dendritic transport, 
axonal and dendritic growth) [6]. Apart of its 
main functions in energy, Cr was recently 
suggested as neurotransmitter or neuromodulator. 
Indeed, neurons can release Cr in an action 
potential-dependent manner [3], and a 
mechanism of Cr recapture from the synaptic 
cleft may exist through SLC6A8 [48]. Cr was 
also suggested as one of the essential CNS 
osmolytes [2,8], and as one potential appetite and 
weight regulator through action on specific 
hypothalamic nuclei [32]. 
 
2.2 AGAT, GAMT and SLC6A8 in CNS 
It has long been thought that most of brain Cr 
was of peripheral origin, be it taken from the diet 
or synthesized endogenously through AGAT and 
GAMT activities in kidney and liver respectively 
[21,72]. However, Cr is synthesized in the 
mammalian brain [50,69], in nerve cell lines as 
well as in primary and organotypic brain cell 
cultures [20,27,30]. AGAT and GAMT are 
expressed in all the main structures of the brain, 
in every main cell types (neurons, astrocytes and 
oligodendrocytes; [11,54,65]). Moreover, we 
have shown that in most region of the rat CNS, 
AGAT and GAMT rarely appear co-expressed 
within the same cell [15]. Organotypic rat 
cortical cultures, primary brain cell cultures 
(neuronal, glial or mixed) and neuroblastoma cell 
lines have a Cr transporter activity [3,16,44]. In 
vivo, mouse and rat CNS can take up Cr from the 
blood against its concentration gradient [47,49]. 
SLC6A8 is expressed throughout the main 
regions of the adult mammalian brain [11,42,65]. 
It was demonstrated that SLC6A8 is found in 
neurons and oligodendrocytes but, in contrast to 
AGAT and GAMT, cannot be detected in 
astrocytes [11], except for very rare ones in 
cerebellum [42]. In contrast to its absence in 
astrocytes lining microcapillaries, SLC6A8 is 
present in MCEC making BBB [11,47,65]. 
 
2.3 Brain creatine: endogenous synthesis 
or uptake from periphery? 
The discovery that SLC6A8 cannot be detected in 
astrocytes, particularly in their feet sheathing 
MCEC, made us suggest that in mature CNS, 
BBB has a limited permeability for Cr, despite 
SLC6A8 expression by MCEC and their capacity 
to import Cr [1,11,45,47,65]. In vivo data 
confirmed this hypothesis: the blood to brain 
transport of Cr through BBB is effective in rats 
and mice but is relatively inefficient [47,49], and 
long term treatment of AGAT- and GAMT-
deficient patients with high doses of Cr allows 
only a slow and in most cases partial 
replenishment of their brain Cr pools (see below) 
[55,63]. One strong argument in favor of the 
“brain endogenous Cr synthesis” hypothesis 
comes from Cr measures in the cerebrospinal 
fluid (CSF) of Cr-deficient patients (see below) 
[18]. SLC6A8 deficient patients present normal 
Cr levels in CSF, but are unable to import Cr 
from periphery [7,23,29,51]. In contrast, GAMT-
deficient patients show strongly decreased levels 
of Cr in CSF but are able to import Cr from the 
blood [57,62]. This also suggests that Cr 
synthesis in the brain might still remain 
operational, although very partially, under 
SLC6A8 deficiency, while it is completely 
blocked in AGAT and GAMT deficiencies. 
Endogenous synthesis, or a very efficient uptake 
from periphery, are the two ways available for 
the brain to secure Cr homeostasis for its energy 
and functions. As uptake from periphery does not 
appear efficient, CNS might privilege Cr 
endogenous synthesis. The brain capacity for Cr 
synthesis would thus depend on the efficient 
supply of arginine, the limiting substrate for Cr 
synthesis, from blood to CNS, and then also on 
local trafficking of arginine between brain cells. 
We and others have shown that cationic amino 
acid transporters (CATs) CAT1, CAT2(B) and 
CAT3 might fulfill these roles in the brain 
[10,17,35]. 
The hypothesis of endogenous Cr synthesis in 
the brain might seem contradictory with the in 
vivo characteristics of SLC6A8 deficiency (see 
below), which, despite AGAT and GAMT 
expression in CNS, presents an absence (or a 
very low level) of brain Cr by magnetic 
resonance spectroscopy (MRS) [53]. This 
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apparent contradiction is probably explained by 
our recent data on AGAT, GAMT and SLC6A8 
expression patterns in the brain. AGAT and 
GAMT are found in every CNS cell type [11], 
but appear rarely co-expressed within the same 
cell [15]. This suggests that to allow Cr synthesis 
in the brain, GAA must be transported from 
AGAT- to GAMT-expressing cells. This GAA 
transfer most probably occurs through SLC6A8, 
as shown in the same study by Cr and GAA 
competition studies and the use of stable isotope-
labeled GAA, demonstrating its uptake by brain 
cells followed by its conversion to Cr by GAMT 
activity [15]. These observations may explain the 
Cr absence in CNS of SLC6A8-deficient patient, 
despite normal expression of AGAT and GAMT 
in their brain [6,18]. Recent studies also 
demonstrate the potential role of SLC6A8 for 
GAA transport across BBB and in brain 
parenchymal cells [64,66].  
 
2.4 Cr in developmental versus adult CNS 
As described above, the adult (or mature) brain 
might privilege Cr endogenous synthesis versus 
uptake from periphery, due to low permeability 
of BBB for Cr and thank to the expression of 
AGAT and GAMT in CNS parenchyma. Fetal 
and perinatal (or immature) CNS probably 
behaves differently for its Cr needs. Fetal needs 
in Cr are partly supported by active transport of 
Cr from mother and embryo [28,36]. AGAT, 
GAMT and SLC6A8 are also well expressed 
during vertebrate embryogenesis, including in the 
brain [19,37,54]. We have shown that AGAT and 
GAMT are expressed in the whole developing 
CNS parenchyma [19]. However, their low level 
(GAMT in particular) at early developmental 
stages suggests that in contrast to adult brain, 
embryonic CNS depends predominantly on 
external Cr supply, be it from embryonic 
periphery or from maternal origin. This is 
coherent with SLC6A8 expression in the whole 
embryonic CNS already at early stages (E12.5 in 
rat), with particularly high levels in 
periventricular zone and choroid plexus, the 
predominant metabolic exchange zones of fetal 
CNS before microcapillary angiogenesis and 
differentiation of BBB [14,19]. 
 
3 Creatine deficiency syndromes 
CNS is the main organ affected in patients 
suffering from Cr deficiency syndromes, inborn 
errors of Cr biosynthesis and transport caused by 
AGAT, GAMT or SLC6A8 deficiency which are 
characterized by an absence or a severe decrease 
of Cr in CNS as measured by MRS [38,53,62]. 
As the prevalence of SLC6A8 deficiency was 
estimated at 2% of all X-linked mental 
retardations [52] and at 1% of males with mental 
retardation of unknown etiology [26], while all 
combined Cr deficiencies were estimated 
between 0.3% and 2.7% of all mental retardation 
[4,41], Cr deficiency syndromes appear as some 
of the most frequent inborn errors of metabolism 
(IEM). 
Cr-deficient patients present neurological 
symptoms in infancy, such as mental retardation 
and delays in speech acquisition; GAMT 
deficiency exhibits a more complex phenotype, 
including intractable epilepsy, extrapyramidal 
movement syndromes and abnormalities in basal 
ganglia [63]. The diverse phenotypic spectrum of 
neurological symptoms observed in Cr deficiency 
syndromes demonstrate the importance of Cr for 
psychomotor development and cognitive 
functions. The more complex phenotype of 
GAMT deficiency is probably due to the toxicity 
of brain GAA accumulation [56], which may 
occur through activation of GABAA receptors by 
GAA [46] or inhibition of the complex between 
Na
+
/K
+
-ATPase and CK [73]. Severe epilepsy is 
also observed sometimes in SLC6A8-deficient 
patients [43]. This may be due to the observed 
CNS GAA accumulation in some SLC6A8-
deficient patients [59], that could be caused by 
impairment of GAA transport through deficient 
SLC6A8, from AGAT- to GAMT-expressing 
brain cells (see below) [15]. 
AGAT- and GAMT-deficient patients can be 
treated by oral supplementation of Cr. While this 
strongly improves their neurological status and 
CNS development, very high doses of Cr must be 
used, and replenishment of cerebral Cr takes 
months and only results, in most cases, in partial 
restoration of cerebral Cr pools [5,33,38,61]. The 
pre-symptomatic treatment of AGAT- and 
GAMT-deficient patients appears to improve 
even more their clinical outcome [55]. For 
GAMT-deficient patients, combined arginine 
restriction and ornithine substitution coupled to 
Cr treatment decrease GAA and also improve 
clinical outcome [56,58]. However, despite 
improvement of clinical outcome by Cr 
supplementation, most AGAT- and GAMT-
deficient patients remain with CNS 
developmental problems. Oral supplementation 
of Cr is inefficient in replenishing brain Cr in 
SLC6A8-deficient patients, who remain with 
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mental retardation, severe speech impairment and 
progressive brain atrophy [7,23,29,51]. Attempts 
to treat SLC6A8-deficient patients with arginine 
and glycine as precursors of Cr gave encouraging 
results in two SLC6A8-deficient patients [25,71], 
while it failed to improve the neurological status 
of four others [31]. 
 
 
4 Secondary creatine deficiencies in 
CNS 
Several other CNS pathologies can lead to a 
secondary Cr deficiency in brain cells. Excess of 
ammonium (NH4
+
)
 
in CNS, as seen in pediatric 
patients under various acquired or inherited 
disorders like urea cycle diseases, can cause 
irreversible damages to the developing brain 
[13,22,40]. NH4
+ 
exposure generates a secondary 
Cr deficiency in brain cells [16,20], eventually 
leading to energy deficit, oxidative stress and cell 
death [12,13]. Ischemic stroke in CNS leads to a 
rapid diminution in brain total Cr (Cr + PCr), 
causing a decrease in high energy phosphates 
production which leads to a failure in most 
energy-dependent processes necessary for cell 
survival [39]. Gyrate atrophy of the choroid and 
retina, an IEM caused by mutations in ornithine 
-aminotransferase (OAT) [68], generates a 
secondary Cr deficiency [60] which in CNS may 
contribute to GA neurological symptoms [67]. 
 
5 Model for creatine synthesis and 
trafficking in CNS 
Altogether, (i) the absence of Cr within the brain 
of Cr-deficient patients, (ii) the CNS expression 
patterns of AGAT, GAMT and SLC6A8, (iii) the 
low permeability of BBB for Cr, and (iv) the 
brain levels of Cr and GAA both in normal and 
Cr-deficient conditions, lead us to propose the 
following concept for Cr synthesis and 
trafficking within CNS [6]. In normal conditions, 
SLC6A8 is expressed by MCEC, but not by the 
surrounding astrocytic feet, implying that limited 
amounts of Cr enter the brain through BBB. In 
most brain regions, brain cells express AGAT 
and GAMT in a cell-dissociated way, and GAA 
must be transported from AGAT- to GAMT-
expressing cells by SLC6A8 for Cr synthesis to 
occur. In AGAT and GAMT deficiency, no Cr 
can be synthesized within CNS, but SLC6A8 
expression in MCEC allows the limited entry of 
Cr within the brain, and thus their treatment by 
oral Cr and the partial replenishment of the brain 
Cr pools. The GAMT-deficient brain 
accumulates GAA. Cr transporter-deficient 
patients lack functional SLC6A8 on MCEC, and 
thus cannot be treated by oral Cr. Their 
endogenous CNS Cr synthesis pathway is also 
deficient, as in most brain regions, GAA cannot 
cross from AGAT- to GAMT-expressing cells 
due to their lack in functional SLC6A8. 
 
 
6 Creatine as therapeutic potential 
for brain diseases  
Troubles in CNS energy metabolism due to 
mitochondrial dysfunction, either from oxidative 
stress, mitochondrial DNA deletions, 
pathological mutations or altered mitochondria 
morphology, play critical roles in the progression 
of neurological diseases as a primary or 
secondary mechanism in neuronal death cascade 
[24]. Cr is known to play essential roles in 
stabilizing mitochondrial function and in 
decreasing neuronal cell death, and Cr 
supplementation was shown to improve the 
bioenergetic deficit associated with several brain 
pathologies, including Huntington’s, Parkinson’s 
and Alzheimer’s diseases, amyotrophic lateral 
sclerosis, stroke and hyperammonemia [6,34]. 
 
 
7 Conclusions 
Cr plays its main role in energy metabolism, 
allowing ATP regeneration through CK 
enzymatic activity. In recent years, new roles of 
Cr have been suggested in CNS, like a function 
of neuromodulator or even true neurotransmitter. 
The recent years have brought new knowledge on 
Cr metabolism and transport in the brain, 
allowing a better understanding on the 
pathophysiology of Cr deficiency syndromes in 
brain cells [6]. In particular, there is evidence that 
BBB presents a low permeability for Cr, and that 
CNS must ensure parts of its needs in Cr by 
endogenous synthesis. Moreover, in many 
regions of the brain, Cr endogenous synthesis 
appears to be dissociated, GAA needing to be 
transported by SLC6A8 from AGAT- to GAMT-
expressing cells for Cr synthesis to occur [15,18]. 
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